Quantcast
Last updated on April 24, 2014 at 10:33 EDT

Latest Bite Stories

2010-03-09 15:01:00

BETHESDA, Md., March 9 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) announced today that it is offering to sell, subject to market and other conditions, 10 million shares of common stock in an underwritten public offering. In connection with the offering, the Company expects to grant the underwriters a 30-day option to purchase an additional 1.5 million shares of common stock from the Company. All of the shares in the offering are being offered by Micromet. Goldman, Sachs...

2010-03-04 06:30:00

BETHESDA, Md., March 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones. "With our lead product candidate blinatumomab expected to begin a European pivotal...

2010-02-25 15:02:00

BETHESDA, Md., Feb. 25 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that the Company will participate in the 2010 RBC Capital Markets Healthcare Conference, to be held March 2 - 3, 2010 in New York City. Christian Itin, Ph.D., the Company's President and CEO, will participate in a panel discussion titled New Targets in Cancer Therapy on March 2, 2010 at 8:00 AM ET. The panel discussion will be webcast live and may be accessed at:...

2010-02-25 15:01:00

BETHESDA, Md.,, Feb. 25 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will host a conference call and audio webcast to review its fourth quarter and full year 2009 results on Thursday, March 4, 2010, at 8:30 AM ET. To participate in the conference call, please dial 800-659-1942 (domestic) or 617-614-2710 (international) and reference the access code 85243244. The presentation will be available via webcast at...

2010-02-10 10:00:00

BETHESDA, Md., Feb. 10 /PRNewswire-FirstCall/ -- At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S. "We are very pleased with the strong support...

2010-02-04 07:01:00

BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will host a Research & Development Day for the investment community on Wednesday, February 10, 2010 from 8:00 AM - 11:00 AM ET at the Yale Club in New York City. Members of the Company's leadership team will outline near-term development plans for the Company's lead product candidate blinatumomab (MT103) and will provide an update on the Company's earlier stage BiTE®...

2010-02-04 07:00:00

BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that the Company will participate in the 12th Annual BIO CEO & Investor Conference, to be held February 8th - 9th in New York City. Christian Itin, Ph.D., the Company's President and CEO, will present a 25 minute corporate overview on February 9th at 11:00 AM ET. The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet-inc.com. A replay of the...

2010-01-07 07:00:00

BETHESDA, Md., Jan. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will participate in the 28th Annual J.P. Morgan Healthcare Conference, to be held January 11th - 14th in San Francisco. Christian Itin, Ph.D., Micromet's President and CEO, will present a 30 minute corporate overview on Thursday, January 14th at 12:30 PM PST. The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet-inc.com. A replay of...

2009-12-08 09:00:00

NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL). The data were presented in an oral presentation(1) at the 51st Annual Meeting of the American Society of Hematology (ASH) and were...

2009-12-07 06:00:00

NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a poster(1) with new data from its ongoing phase 1 clinical trial of its product candidate blinatumomab in patients with non-Hodgkin's lymphoma (NHL) at the 51ST Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana....


Latest Bite Reference Libraries

0_e288c9a7e7e932afbeba3516c20e64f2
2009-06-16 22:38:30

The Brown Recluse Spider (Loxosceles reclusa) is a species of arachnid that is native to the USA from the southern Midwest south to the Gulf of Mexico. It can be found in Canada as well around southeast Ontario, and southern Quebec. Its range lies from southeastern Nebraska through southern Iowa, Illinois, and Indiana to southwestern Ohio. In the south, it is native from central Texas to western Georgia. It is not usually found west of the Rocky Mountains. Contrary to popular belief, this...

More Articles (1 articles) »